What is the mechanism of pseudopseudohypoparathyroidism (PPHP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanism of Pseudopseudohypoparathyroidism

Pseudopseudohypoparathyroidism (PPHP) results from paternally inherited heterozygous inactivating mutations in the GNAS gene encoding the Gsα protein, causing the physical features of Albright hereditary osteodystrophy (AHO) without hormone resistance due to tissue-specific genomic imprinting. 1, 2, 3

Genetic Basis

  • PPHP is caused by heterozygous inactivating mutations within the GNAS gene exons that encode the alpha-subunit of the stimulatory G protein (Gsα), which is essential for parathyroid hormone (PTH) and other hormone signaling 4, 5

  • The same GNAS mutations that cause pseudohypoparathyroidism type Ia (PHP-Ia) when maternally inherited will cause PPHP when paternally inherited 3, 5

  • Multiple different mutation types have been identified, including deletions (p.Asp189_Tyr190delinsMetfxX14), frameshifts (p.Val117fsX23, p.Tyr190CysfsX19), and splicing mutations (c.659 + 1G>A) 2

Imprinting Mechanism Explaining the Phenotype

  • The critical distinction between PPHP and PHP-Ia is explained by parent-of-origin-specific (genomic imprinting) expression of Gsα in hormone-responsive tissues 4, 5

  • In renal proximal tubules and certain other endocrine target tissues, Gsα is expressed predominantly or exclusively from the maternal allele due to tissue-specific imprinting 4, 5

  • When the GNAS mutation is inherited from the father (PPHP), the paternal allele is already silenced by imprinting in these tissues, so the functional maternal allele remains intact and hormone signaling proceeds normally 5

  • When the same mutation is inherited from the mother (PHP-Ia), the functional maternal allele is disrupted while the paternal allele remains silenced, resulting in marked reduction of Gsα levels and hormone resistance 4

Clinical Manifestations

  • Patients with PPHP exhibit the somatic features of Albright hereditary osteodystrophy (AHO), including short stature, round facies, subcutaneous ossifications, brachydactyly, and obesity 1, 2, 3

  • Unlike PHP-Ia patients, those with PPHP do not develop resistance to PTH, thyroid-stimulating hormone (TSH), or other hormones, maintaining normal calcium homeostasis and thyroid function 3, 5

  • Subcutaneous calcification can appear as an early manifestation of AHO, sometimes presenting as early as 7 months of age 2

Haploinsufficiency Component

  • The combination of tissue-specific genomic imprinting and haploinsufficiency explains why PPHP patients have AHO features despite lacking hormone resistance 5

  • In tissues where Gsα is expressed from both alleles (non-imprinted tissues), having only one functional copy (50% Gsα activity) is sufficient to cause the developmental abnormalities characteristic of AHO 5

  • This haploinsufficiency model also explains why not all Gs-mediated hormone actions are affected equally in PHP-Ia, as different tissues have varying degrees of imprinting 5

References

Research

Clinical characterization and molecular classification of 12 Korean patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2013

Research

Genetics of pseudohypoparathyroidism: bases for proper genetic counselling.

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2008

Research

The GNAS locus and pseudohypoparathyroidism.

Advances in experimental medicine and biology, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.